Cancer Research and Foundation News
CHRISTUS Health ranked fourth among large companies in the Houston area in an employee survey by WorkplaceDynamics. With more than a century of service to health, CHRISTUS places emphasis on its core values: dignity, integrity, excellence, compassion and stewardship, helping it become a leader in employee satisfaction.
New research indicates that a protein called TWIST plays a key role in the aggressiveness and progression of breast cancers by regulating estrogen receptor (ER) expression. This discovery may ultimately open the door to new treatments for ER-negative breast cancers, which are more aggressive and harder to treat than ER-positive breast cancers.
Researchers from NCI’s Center for Cancer Research (CCR) led by Dr. Hisataka Kobayashi have developed a new type of targeted anticancer treatment using photoimmunotherapy—a light-activated “nano-bomb” bound to a monoclonal antibody (mAb) that delivers the cellular disruptor to tumor cells.
